Instem plc Notice of Results & Investor Presentation (7321I)

TIDMINS

RNS Number : 7321I

Instem plc

20 April 2022

Instem plc

("Instem" or the "Company")

Notice of Results

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will announce results for the year ended 31 December 2021 on Tuesday 26 April 2022.

Analyst Presentation: 09.30, Tuesday 26 April

Management will be hosting a presentation via web conference on the day of the results at 09.30. Analysts wishing to join should register their interest by emailing instem@walbrookpr.com or by telephoning 020 7933 8780.

Investor Presentation: 16:00, Tuesday 26 April

Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects at 16:00 on the day, through the digital platform Investor Meet Company. Investors can sign up for free and add to attend the presentation via the following link https://www.investormeetcompany.com/instem-plc/register-investor

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

For further information, please contact:

 
 Instem plc                               Via Walbrook 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 Singer Capital Markets (Nominated 
  Adviser & Broker)                       +44 (0) 20 7496 3000 
 Peter Steel 
  Alex Bond 
  Rachel Hayes 
 
 Stifel Nicolaus Europe Limited (Joint 
  Broker)                                 +44 (0) 20 7710 7600 
 Ben Maddison 
 Alex Price 
 
 Walbrook Financial PR                    +44 (0) 20 7933 8780 
 Tom Cooper                               instem@walbrookpr.com 
 Nick Rome

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

   To learn more about Instem solutions and its mission, please visit   www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORURRWRUSUSURR

(END) Dow Jones Newswires

April 20, 2022 04:05 ET (08:05 GMT)

Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024